Ziconotide (Prialt) — CPB 0712 | AETNA Coverage Update

Aetna modified CPB 0712 for ziconotide (Prialt) intrathecal infusion, effective November 27, 2025. Here's what billing teams need to know before submitting claims under J2278.

Aetna, a CVS Health company, updated its ziconotide coverage policy under CPB 0712 Aetna system. This policy governs intrathecal (IT) administration of ziconotide (Prialt) for severe chronic pain. The primary billing code is J2278 (injection, ziconotide, 1 mcg), supported by a suite of CPT procedure codes in the 62320–62362 range for intrathecal injections and pump implantation. If your practice manages intrathecal drug delivery systems for pain patients with Aetna coverage, this update sets the exact criteria that will determine medical necessity approval or claim denial.

Quick-Reference Table

Aetna Ziconotide Coverage Criteria and Medical Necessity Requirements 2025

Aetna's ziconotide coverage policy has a clear, narrow gate for medical necessity. IT administration of ziconotide (Prialt) is covered for members with severe chronic pain who meet one of two conditions: they are intolerant of other treatments, or they are refractory to them. Those other treatments include systemic analgesics, adjunctive therapies, and IT morphine.

Read that carefully. Aetna is not treating ziconotide as a second-line drug. It's a last resort. Your documentation must show that the patient either tried and failed IT morphine or has a clinical reason they cannot tolerate it. Without that trail in the chart, your prior authorization request for J2278 will not hold up.

The policy is explicit about contraindications that flip coverage from medically necessary to not medically necessary. Any member with one of the following conditions does not qualify:

These aren't soft exclusions. They are hard stops. If any of these appear in the member's chart, Aetna will not cover ziconotide billing under any of the procedure codes in this policy — not CPT 62320 through 62327 for injections, not 62350 or 62351 for catheter tunneling, and not 62360–62362 for pump implantation or replacement.

Flag this now with your prior auth team. When you submit a prior authorization for J2278 or the associated pump codes (E0783, E0785, E0786), the submitting clinician's documentation needs to affirmatively address each contraindication. Missing one is the fastest route to a claim denial on a high-cost drug.

Aetna Ziconotide Exclusions and Non-Covered Indications

This is where the policy gets expensive if your team isn't paying attention. Aetna classifies ziconotide as experimental, investigational, or unproven for six specific conditions — plus one combination therapy. None of these will get reimbursement under CPB 0712.

Conditions where ziconotide is experimental (any route of administration):

The route of administration matters here too. Aetna calls out "IT administration or other routes" as experimental for these indications. That means off-label use in any delivery method is excluded.

There's also a specific carve-out for combination therapy. The intrathecal combination of ziconotide, morphine, and levobupivacaine for cancer-related refractory pain is explicitly listed as experimental. This is a meaningful distinction for oncology pain practices. Even if the patient has qualifying cancer ICD-10 codes (C00.0–D09.9), using that triple combination negates coverage. You'd be billing J2278 alongside J2270 or J2272 (morphine sulfate) — and Aetna will deny the claim as unproven.

If you serve oncology patients with complex pain regimens, talk to your compliance officer before the November 27, 2025 effective date. The line between covered IT ziconotide monotherapy and non-covered combination therapy can be thin in practice.

Coverage Indications at a Glance

Aetna Ziconotide Billing Guidelines and Action Items 2025

The policy is effective November 27, 2025. That's your deadline. Here are the actions to take now.

1. Audit your J2278 charge capture against the updated medical necessity criteria.
Every claim for ziconotide injection (J2278) needs supporting documentation showing the patient failed or is intolerant of systemic analgesics, adjunctive therapies, and IT morphine. If that documentation isn't in the record before you bill, fix it before November 27.

2. Build a contraindication screening checklist into your prior auth workflow.
Before you submit any prior authorization for J2278 or pump codes E0783/E0785/E0786, the submitting provider must actively screen for all four contraindications: psychosis history, injection site infection, bleeding diathesis, and spinal canal obstruction. A single missed contraindication turns a medically necessary claim into a denial.

3. Flag all oncology patients receiving IT ziconotide combination regimens.
If any patient is currently on the ziconotide + morphine + levobupivacaine combination for cancer pain, that regimen is experimental under this policy. Pull those charts now. Understand whether you're billing J2278 alongside J2270, J2272, or S0093. If you are, expect denials on new claims after November 27, 2025.

4. Review your ICD-10 pairings for the experimental exclusion diagnoses.
Claims for ziconotide billing paired with F84.0 (autism), G12.23 (primary lateral sclerosis), migraine codes (G43.001–G43.919), epilepsy codes (G40.001–G40.C19), or stroke/cerebrovascular codes (I63.x, G45.x, I65–I68) will be denied. If those diagnoses appear in the member's problem list but the pain indication is separate, make sure your primary diagnosis on the claim reflects the pain condition (G89.x), not the excluded condition.

5. Confirm home infusion billing aligns with pump and catheter code requirements.
If your practice bills home infusion for ziconotide, review CPT 99601 and 99602 alongside the pump HCPCS codes (E0779, E0780, E0781, E0783). The infusion pump billing — particularly for implantable programmable pumps (E0783, E0786) and catheter replacements (E0785) — needs to match the approved device type and the clinical documentation. Aetna's ziconotide coverage policy requires IT delivery; any deviation from intrathecal administration puts the claim at risk.

CPT, HCPCS, and ICD-10 Codes for Ziconotide Under CPB 0712

Covered HCPCS Code (When Selection Criteria Are Met)

Related CPT Procedure Codes (Intrathecal Injection and Pump Implantation)

These codes support billing for the procedures used to administer ziconotide. Coverage depends on medical necessity criteria being met for J2278.

Related HCPCS Equipment and Drug Codes

Key ICD-10-CM Diagnosis Codes